Dr. Kai Zu, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
5555 Grossmont Center Dr
La Mesa, CA 91942
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 579
Licensed in California since 2001, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A74842 (first issued 2001; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sharp Memorial Hospital San Diego, CA
- Grossmont Hospital La Mesa, CA
- Sharp Chula Vista Medical Center Chula Vista, CA
- Sharp Coronado Hospital and Hlthcr Ctr Coronado, CA
Medical groups
- Cancer Center Oncology Medical Group Inc - East County (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 579
- Services billed
- 320,547
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 73,675 | 35 |
| Injection, ferric carboxymaltose, 1 mg | 59,250 | 36 |
| Injection, nivolumab, 1 mg | 50,040 | 14 |
| Injection, denosumab, 1 mg | 4,020 | 16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,015 | 30 |
| Injection, palonosetron hcl, 25 mcg | 1,540 | 26 |
| Established patient office or other outpatient visit, 20-29 minutes | 803 | 379 |
| Injection of drug or substance under skin or into muscle | 485 | 67 |
| Injection of additional new drug or substance into vein | 405 | 36 |
| Administration of chemotherapy into vein, 1 hour or less | 375 | 53 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in La Mesa, CA | 125 |
| Ondansetron Hcl Other prescribers in La Mesa, CA | 90 |
| Omeprazole Other prescribers in La Mesa, CA | 69 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in La Mesa, CA | 65 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in La Mesa, CA | 60 |
| Brukinsa (zanubrutinib) | 49 |
| Prednisone Other prescribers in La Mesa, CA | 48 |
| Potassium Chloride Other prescribers in La Mesa, CA | 47 |
| Levothyroxine Sodium Other prescribers in La Mesa, CA | 38 |
| Lenalidomide | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 34 companies reported 70 payments worth $2,344 in total to this clinician.
| Daiichi Sankyo Inc. | $650 |
|---|---|
| Celgene Corporation | $221 |
| Pfizer Inc. | $150 |
| Novartis Pharmaceuticals Corporation | $102 |
| Beone Medicines USA, Inc. | $99.52 |
| Merck Sharp & Dohme LLC | $86.72 |
| Genzyme Corporation | $80.91 |
| GlaxoSmithKline, LLC. | $76.24 |
| Food and Beverage | $1,678 |
|---|---|
| Consulting Fee | $650 |
| Education | $15.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Legend Biotech USA Inc. Jul 24, 2025 | Education CARVYKTI · Oncology · in-kind | $15.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,150 in research payments for these studies, mostly to the institutions running them.
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Eli Lilly and Company · Active, not recruiting · NCT04965493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.